Report Scope
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, and diagnostic kits, recently launched or in development. Market share, market deterrents, unmet needs and other factors that drive research are also discussed, while patents that highlight research priorities and predict future trends are analyzed.
Specifically, outside the scope of research are vector/mosquito control approaches, strategies and products, drugs used for symptomatic treatment and not for the elimination of the virus from the host, and details on suppliers of generics and non-branded generics. Also excluded are markets for hospital-based diagnosis that are not carried out by kits (for example, malaria slide smear-based tests), as well as discussion on the spread of vector-borne infection (such as malaria) via blood transfusion.
The publisher categorizes the markets based on regions defined by WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships for a large number of infectious diseases. Regions include Africa, the Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific.
Report Includes
- 113 tables
- An updated review of the global markets for infectious disease treatments in the healthcare and pharmaceutical industry
- Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Evaluation and forecast the overall market size in dollar value terms, and corresponding market share analysis by disease type and geographic region
- Highlights of the market potential for infectious disease treatments, opportunities and gaps estimating current and future demand; and impact of COVID-19 on the progress of this market
- Emphasis on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development
- Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
- Technology assessment of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated
- Insight into the competitive landscape featuring key mergers and acquisitions (M&A), collaboration agreements, and company revenue share analysis across the global infectious diseases market
- Review of key patent grants and new technologies with relation to innovations in infectious disease treatments
- Company profiles of the leading industry participants including Abbott, AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, and Roche
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- What's New in This Update?
- Geographic Breakdown
- Analyst's Credentials
- Publisher Custom Research
- Related Publisher Research Reports
Chapter 2 Summary and Highlights
- Chapter 3 Overview
- Top Global Causes of Death
- Infectious Diseases
- Classification of Infectious Agents
- Classification of Modes of Transmission
- Management of Infectious Diseases
- Bacterial Infectious Diseases
- Viral Infectious Diseases
- Protozoan Infectious Diseases
- Factors Responsible for Emergence and Spread
- Vaccines
- Antibiotics
- Mechanism of Action
Chapter 4 Disease Overview
- Hepatitis B and Hepatitis C
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Herpes Simplex Virus
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- HIV/AIDS
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Influenza A and Influenza B
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Rotavirus
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Respiratory Syncytial Virus
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Malaria
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Tuberculosis
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Viral Hemorrhagic Fevers-Lassa Fever
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Viral Hemorrhagic Fevers-Ebola Fever
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Response to Manage Ebola
- Diagnosis
- Treatment
- Viral Hemorrhagic Fevers-Marburg
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Viral Hemorrhagic Fevers-Zika Virus
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Viral Hemorrhagic Fevers-Yellow Fever
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
- Viral Hemorrhagic Fevers-Dengue
- Incidence and Geographical Distribution
- Risk Factors
- Etiology and Symptoms
- Socioeconomic Burden
- Diagnosis
- Treatment
Chapter 5 Market Dynamics
- Infectious Diseases
- Drivers
- Deterrents
- Hepatitis B
- Drivers
- Deterrents
- Unmet Needs
- Hepatitis C
- Drivers
- Deterrents
- Unmet Needs
- Herpes
- Drivers
- Deterrents
- Unmet Needs
- HIV/AIDS
- Drivers
- Deterrents
- Unmet Needs
- Influenza A and B
- Drivers
- Deterrents
- Rotavirus
- Drivers
- Deterrents
- Unmet Needs
- Respiratory Syncytial Virus
- Drivers
- Deterrents
- Unmet Needs
- Malaria
- Drivers
- Deterrents
- Unmet Needs
- Tuberculosis
- Drivers
- Deterrents
- Unmet Needs
- MERS-CoV
- Drivers
- Deterrents
- Unmet Needs
- Viral Hemorrhagic Fevers-Lassa
- Drivers
- Deterrents
- Unmet Needs
- Viral Hemorrhagic Fevers-Ebola
- Drivers
- Deterrents
- Viral Hemorrhagic Fevers-Marburg
- Drivers
- Deterrents
- Unmet Needs
- Viral Hemorrhagic Fevers-Zika
- Drivers
- Deterrents
- Viral Hemorrhagic Fevers-Yellow Fever
- Drivers
- Deterrents
- Unmet Needs
- Viral Hemorrhagic Fevers-Dengue
- Drivers
- Deterrents
- Unmet Needs
Chapter 6 Impact of COVID-19
- History of Outbreak
- Symptoms of COVID-19
- Progression of COVID-19
- Incubation Period
- Epidemiology
- Impact of COVID-19 on Infectious Disease Market
Chapter 7 Markets and Forecast
- Global Market for Infectious Disease Treatments
- Global Market for Infectious Disease Treatments by Region
- Global Market for Infectious Disease Therapeutics by Disease Type
- Global Market for Infectious Disease Vaccines by Disease Type
- Global Market for Infectious Disease Diagnostics by Disease Type
- Global Infectious Diseases
- Hepatitis B and Hepatitis C
- Herpes Simplex Virus
- HIV/AIDS
- Influenza-A and B
- Rotavirus
- Respiratory Syncytial Virus
- Malaria
- Tuberculosis
- MERS-CoV
- Viral Hemorrhagic Fevers
Chapter 8 Antibiotic Resistance
- Overview
- Mechanisms of Antibiotic Resistance
- Reasons for Antibiotic Resistance
- Antibiotic Resistance-Incidence
- New Antibiotics in Development
Chapter 9 Research and Development
- Overview
- Hepatitis B and Hepatitis C
- Herpes Simplex Virus
- HIV/AIDS
- Influenza A and Influenza B
- Rotavirus
- Respiratory Syncytial Virus
- Malaria
- Tuberculosis
- MERS
- Hemorrhagic Fevers
- Dengue
- Ebola
- Lassa fever
- Marburg
- Yellow Fever
- Zika
Chapter 10 Next-Generation Predictive Tools
- Overview
- Why Do We Need Forecast Tools?
- Tools in Infectious Disease Modeling
- Mobile Apps in Infectious Disease Modeling
- Current Limitations in Infectious Disease Modeling
Chapter 11 Patent Analysis
- Hepatitis B
- Key Patents
- Hepatitis C
- Key Patents
- Herpes Simplex Virus
- Key Patents
- HIV/AIDS
- Key Patents
- Influenza
- Key Patents
- Rotavirus
- Key Patents
- Respiratory Syncytial Virus
- Key Patents
- Malaria
- Key Patents
- Tuberculosis
- Key Patents
- MERS-CoV
- Key Patents
- Viral Hemorrhagic Fevers-Lassa
- Key Patents
- Viral Hemorrhagic Fevers-Ebola
- Key Patents
- Viral Hemorrhagic Fevers-Marburg
- Key Patents
- Viral Hemorrhagic Fevers-Zika
- Key Patents
- Viral Hemorrhagic Fevers-Dengue
- Key Patents
- Viral Hemorrhagic Fevers-Yellow Fever
Chapter 12 Competitive Landscape
- Mergers and Acquisitions and Collaborations
- Market Share of Infectious Disease Market
- Market for Hepatitis B and Hepatitis C
- Market Shares of HIV/AIDS Therapeutics
- Market Shares of Influenza Vaccines
- Market Shares of Rotavirus Vaccines
Chapter 13 Company Profiles
- Abbott
- Abbvie Inc.
- Astrazeneca Pharmaceuticals
- Bristol-Myers Squibb Co.
- Diasorin S.P.A.
- Gilead Sciences Inc.
- Glaxosmithkline
- Johnson & Johnson
- Merck & Co, Inc.
- Novartis Ag
- Orasure Technologies Inc.
- Roche
- Sanofi S.A.
- Seqirus, A Csl Co.
- Siemens Healthineers
Chapter 14 Appendix: Abbreviations
List of Tables
Summary Table: Global Market for Infectious Disease Treatments, by Segment, Through 2026
Table 1: Leading Causes of Death, Worldwide, by Region, 2019
Table 2: Leading Causes of Death Due to Infectious Diseases, by Region, 2019
Table 3: Prevalence and Incidence of Hepatitis B, 2019
Table 4: Prevalence and Incidence of Hepatitis C, 2019
Table 5: Global Death Rate Related to Acute Hepatitis B, 1990-2019
Table 6: Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019
Table 7: Prevalence and Incidence of Genital Herpes, Worldwide, 2005-2019
Table 8: Prevalence of HIV, Adults (15-49 Years Old), by Region, 2020
Table 9: New HIV Infections (per 1,000 Uninfected Population), Among all Ages, by Region, 2020
Table 10: Total Number of New HIV Infections, 2000-2020
Table 11: Cases of HIV/AIDS Related Deaths, 2000-2020
Table 12: Years of Life Lost (YLLs), Pandemic Influenza A, H1N1, by Region, 2009
Table 13: Estimates of Number of RSV Cases per Season for 15 Participating Countries, 2000-2020
Table 14: Death Rates of RSV-Infected Patients, by WHO Region, 2019
Table 15: Global Incidence Rate of Malaria Cases, by Region, 2000-2019
Table 16: Global Confirmed Cases of Malaria in Public Sector, by Region, 2010-2019
Table 17: Deaths Due to Malaria Worldwide, by Region, 2010-2019
Table 18: Global Health Expenditures on Malaria Treatment, by Region, 2019
Table 19: WHO Guidelines for Treatment of Malaria
Table 20: Treatment Regimen, Drug-Susceptible TB
Table 21: MERS-CoV Confirmed Cases and Deaths, by Region, January 2016-October 2021
Table 22: Laboratory Tests for MERS CoV, as Recommended by WHO
Table 23: Lassa Fever, Confirmed Cases and Deaths, by Region, January 2006-April 2020
Table 24: Reported Cases and Deaths in Ebola Outbreaks, 2007-February 2021
Table 25: Reported Cases and Deaths in Marburg Virus, 1998-December 2020
Table 26: Global Health Burden due to Outbreak of Zika Virus, by Country, 2015-2016
Table 27: Potential Cases and Deaths Due to Yellow Fever, 1995-2018
Table 28: Disease Burden–Yellow Fever in Africa, 2019
Table 29: Deaths Averted due to Mass Vaccinations in Africa, 2019
Table 30: Global Prevalence and Incidence of Dengue, 2019
Table 31: COVID-19 Confirmed Cases and Deaths, by Region, as of November 2020
Table 32: Global Market for Infectious Disease Treatment, by Region, Through 2026
Table 33: Global Market for Infectious Disease Therapeutics, by Disease Type, Through 2026
Table 34: Global Market for Infectious Disease Vaccines, by Disease Type, Through 2026
Table 35: Global Market for Infectious Disease Diagnostics, by Disease Type, Through 2026
Table 36: Global Market for Hepatitis B Therapeutics, by Region, Through 2026
Table 37: Global Market for Hepatitis B Vaccines, by Region, Through 2026
Table 38: Global Market for Hepatitis B Diagnostics, by Region, Through 2026
Table 39: Global Market for Hepatitis C Therapeutics, by Region, Through 2026
Table 40: Global Market for Hepatitis C Diagnostics, by Region, Through 2026
Table 41: Global Market for HSV Therapeutics, by Region, Through 2026
Table 42: Global Market for HSV Diagnostics, by Region, Through 2026
Table 43: Global Market for HIV Therapeutics, by Region, Through 2026
Table 44: Global Market for HIV Diagnostics, by Region, Through 2026
Table 45: Global Market for Influenza Vaccines, by Region, Through 2026
Table 46: Global Market for Influenza Diagnostics, by Region, Through 2026
Table 47: Global Market for Rotavirus Vaccines, by Region, Through 2026
Table 48: Global Market for Rotavirus Diagnostics, by Region, Through 2026
Table 49: Global Market for RSV Vaccines, by Region, Through 2026
Table 50: Global Market for RSV Diagnostics, by Region, Through 2026
Table 51: Global Market for Malaria Therapeutics, by Region, Through 2026
Table 52: Global Market for Malaria Vaccines, by Region, Through 2026
Table 53: Global Market for Malaria Diagnostics (RDTs*), by Region, Through 2026
Table 54: Global Market for Tuberculosis Therapeutics, by Region, Through 2026
Table 55: Global Market for Tuberculosis Diagnostics, by Region, Through 2026
Table 56: Global Market for MERS-CoV Vaccines, by Region, Through 2026
Table 57: Global Market for Lassa Fever Vaccines, by Region, Through 2026
Table 58: Global Market for Ebola Fever Vaccines, Through 2026
Table 59: Global Market for Zika Vaccines, by WHO Region, Through 2026
Table 60: Global Market for Yellow Fever Vaccines, by WHO Region, Through 2026
Table 61: Global Market for Dengue Vaccines, by Region, Through 2026
Table 62: Reported Range of Resistant Population Proportion (%), by Region
Table 63: WHO Priority List, Pathogens for R&D of New Antibiotics
Table 64: Global Antibiotics Development Pipeline
Table 65: Hepatitis B and Hepatitis C Development Pipeline
Table 66: Herpes Simplex Virus Development Pipeline
Table 67: HIV/AIDS Development Pipeline
Table 68: Influenza A and Influenza B Development Pipeline
Table 69: Rotavirus Development Pipeline
Table 70: RSV Development Pipeline
Table 71: Malaria Development Pipeline and Recent Launches
Table 72: Tuberculosis Development Pipeline
Table 73: MERS Development Pipeline
Table 74: Dengue Development Pipeline
Table 75: Ebola Development Pipeline
Table 76: Lassa Fever Development Pipeline
Table 77: Marburg Development Pipeline
Table 78: Yellow Fever Development Pipeline
Table 79: Zika Development Pipeline
Table 80: Hepatitis B Published Patent Applications, 2018-2021
Table 81: Hepatitis C Published Patent Applications, 2018-2021
Table 82: Herpes Simplex Virus Published Patent Applications, 2018-2021
Table 83: HIV/AIDS Published Patent Applications, 2018-2021
Table 84: Influenza Published Patent Applications, 2018-2021
Table 85: Rotavirus Published Patent Applications, 2018-2021
Table 86: Respiratory Syncytial Virus Published Patent Applications, 2018-2021
Table 87: Malaria Published Patent Applications, 2018-2021
Table 88: Tuberculosis Published Patent Applications, 2018-2021
Table 89: MERS Published Patent Applications, 2018-2021
Table 90: Lassa Fever Published Patent Applications, 2018-2021
Table 91: Ebola Virus Published Patent Applications, 2018-2021
Table 92: Marburg Virus Published Patent Applications, 2018-2021
Table 93: Zika Published Patent Applications, 2018-2021
Table 94: Dengue Fever Published Patent Applications, 2018-2021
Table 95: Yellow Fever Published Patent Applications, 2018-2021
Table 96: Abbott: Product Portfolio, by Business Segment
Table 97: Abbott: Financials, 2018-2020
Table 98: AbbVie: Business Segments
Table 99: AbbVie: Financial Performance, Through 2020
Table 100: Bristol-Myers Squibb: Financial Performance, 2018-2020
Table 101: Gilead Sciences: Financial Performance, 2018-2020
Table 102: GlaxoSmithKline: Product Segments
Table 103: GlaxoSmithKline: Financial Performance, 2018-2020
Table 104: Johnson & Johnson: Business Segments
Table 105: Johnson & Johnson: Financial Performance, 2018-2020
Table 106: Merck: Business Segments
Table 107: Merck: Financial Performance, 2018-2020
Table 108: Roche: Business Segments
Table 109: Roche: Financial Performance, 2018-2020
Table 110: Sanofi: Business Segments
Table 111: Sanofi: Financial Performance, 2018-2020
Table 112: Abbreviations Used in this Report
List of Figures
Summary Figure: Global Market for Infectious Disease Treatments, by Segment, 2020-2026
Figure 1: 20 Leading Causes of Death, Worldwide, 2019
Figure 2: Leading Causes of Death, Worldwide, by Region, 2019
Figure 3: Leading Causes of Death Due to Infectious Diseases, by Region, 2019
Figure 4: Global Vaccination Coverage, by Vaccine, 2020
Figure 5: Global Death Rate Related to Acute Hepatitis B, 1990-2019
Figure 6: Years of Life (YLLs) Lost Related to Acute Hepatitis B, Worldwide, 2016-2019
Figure 7: Death Rate Related to Acute Hepatitis C, Worldwide, 1990-2019
Figure 8: Years of Life (YLLs) Lost Related to Acute Hepatitis C, Global, 2016-2019
Figure 9: Disability-affected Life Years (DALYs) Caused by Genital Herpes, Worldwide, 1990-2019
Figure 10: New HIV Infections, by Region, Worldwide, 2020
Figure 11: HIV/AIDS Related Deaths, by Region, 2020
Figure 12: Estimated Number of Deaths Due to 2009 Pandemic Influenza A H1N1, by Region, August 2009-August 2010
Figure 13: Number of Deaths Due to Rotavirus, Worldwide, 2015-2019
Figure 14: Highest Number of Infant Deaths Due to Rotavirus, by Country, 2017
Figure 15: Death Caused by Malaria Worldwide, 2015-2019
Figure 16: Global Incidence of Tuberculosis, 2015-2020
Figure 17: Deaths due to Tuberculosis, Worldwide, 1990-2019
Figure 18: Disability-Adjusted Life Years Caused by Tuberculosis, Worldwide, 1990-2019
Figure 19: Incidence of Cases and Deaths from Lassa Fever in Nigeria, 2017-2020
Figure 20: Total Number of Cases due to Ebola Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), March 2014-February 2016
Figure 21: Deaths Due to Ebola Outbreaks in West Africa (Guinea, Liberia, Sierra Leone), March 2014-February 2016
Figure 22: Cases and Deaths Due to Major Marburg Outbreaks, 1998–June 2017
Figure 23: Confirmed Zika Virus Cases in the Americas, 2015-2020
Figure 24: Countries (Y) with Number of Confirmed Zika Cases (X) in the Americas, 2015-2016
Figure 25: Global Disability-Adjusted Life Years (DALYs) Due to Yellow Fever, 1995-2019
Figure 26: Deaths Caused by Yellow Fever, Worldwide, 1995-2019
Figure 27: Total Number of Dengue Cases Reported in the Americas, 2016-2020
Figure 28: Incidence Rate of Dengue in the Americas, 2016-2020
Figure 29: Deaths Caused by Dengue, Worldwide, 2015-2019
Figure 30: Dengue-Caused Years of Life Lost, Worldwide, 2015-2019
Figure 31: Global Market for Hepatitis B Vaccines, by Region, 2019–2026
Figure 32: Global Market for Hepatitis B Vaccines, by Region, 2019–2026
Figure 33: Global Market for Hepatitis B Diagnostics, by Region, 2019-2026
Figure 34: Global Market for Hepatitis C Therapeutics, by Region, 2019-2026
Figure 35: Global Market for Hepatitis C Diagnostics, by Region, 2019–2026
Figure 36: Global Market for HSV Therapeutics, by Region, 2019-2026
Figure 37: Global Market for HSV Diagnostics, by Region, 2019-2026
Figure 38: Global Market for HIV/AIDS Therapeutics, by Region, 2019-2026
Figure 39: Global Market for HIV Diagnostics, by Region, 2019–2026
Figure 40: Global Market for Influenza Vaccines, by Region, 2019-2026
Figure 41: Global Market for Influenza Diagnostics, by Region, 2019-2026
Figure 42: Global Market for Rotavirus Vaccines, by Region, 2019-2026
Figure 43: Global Market for Rotavirus Diagnostics, by Region, 2019-2026
Figure 44: Global Market for RSV Vaccines, by Region, 2019-2026
Figure 45: Global Market for RSV Diagnostics, by Region, 2019-2026
Figure 46: Global Market for Malaria Therapeutics, by Region, 2019-2026
Figure 47: Global Market for Malaria Diagnostics (RDTs*), by Region, 2019-2026
Figure 48: Global Market for Tuberculosis Therapeutics, by Region, 2019-2026
Figure 49: Global Market for Tuberculosis Diagnostics, by Region, 2019-2026
Figure 50: Global Market for MERS-CoV Vaccine, by Region, 2019-2026
Figure 51: Global Market for Lassa Fever Vaccines, by Region, 2020-2026
Figure 52: Global Market for Zika Vaccines, by WHO Region, 2019-2026
Figure 53: Global Market for Yellow Fever Vaccines, by WHO Region, 2019-2026
Figure 54: Global Market for Dengue Vaccines, by Region, 2019-2026
Figure 55: Antibiotic Use* by Class, Select Classes, 2000 and 2010
Figure 56: Shares of Companies in the Global Market for Hepatitis B and C, 2020
Figure 57: Shares of Companies in the Global Market for HIV/AIDS Therapeutics, 2020
Figure 58: Shares of Companies in the Global Market for Influenza Vaccines, 2020
Figure 59: Shares of Companies in the Global Market for Rotavirus Vaccines, 2020
Figure 60: Abbott: Revenue Share, by Region, 2020
Figure 61: Abbott: Revenue Share, by Business Segment, 2020
Figure 62: AbbVie: Net Revenue Share, by Business Segment, 2020
Figure 63: AbbVie: Net Revenue Share, by Region, 2020
Figure 64: Bristol Myers Squibb: Sales Share, by Product, 2020
Figure 65: Bristol-Myers Squibb: Revenue Share, by Region, 2020
Figure 66: Gilead Sciences: Sales Share, by Product, 2020
Figure 67: Gilead Sciences: Revenue Share, by Region, 2020
Figure 68: GlaxoSmithKline: Sales Share, by Product Segment, 2020
Figure 69: GlaxoSmithKline: Revenue Share, by Region, 2020
Figure 70: Johnson & Johnson: Sales Share, by Business Segment, 2020
Figure 71: Johnson & Johnson: Revenue Share, by Region, 2020
Figure 72: Merck: Revenue Share, by Business Segment, 2020
Figure 73: Merck: Revenue Share, by Region, 2020
Figure 74: Roche: Sales Share, by Product Segment, 2020
Figure 75: Roche: Revenue Share, by Region, 2020
Figure 76: Sanofi: Sales Share, by Business Segment, 2020
Figure 77: Sanofi: Sales Share, by Region, 2020
Executive Summary
The global market for infectious diseases (treatment, vaccines and diagnostics) in 2021, was valued at $72.Billion, and is expected to grow to $106.3 Billion by 2026, at a compound annual growth rate (CAGR) of 8% during the forecast period of 2021-2026.
The Americas are the largest market, followed by Europe, throughout the forecast period. Higher cost of treatment accounts for the larger market values in these two markets, even though the number of cases might be lower than other parts of the world. The other markets are also growing, which can be attributed to growing prevalence and increasing awareness coupled with WHO interventions.
Among vaccines, influenza vaccines have the highest market value market with growth in the next few years being driven by conversion to quadrivalent vaccines and immunization of the elderly population. The influenza market is also highly influenced by the COVID-19 pandemic, due to which the sales have gone up. Government intervention has led to increased vaccination during the pandemic period of 2020 and thus contributed to market revenues. In terms of growth, vaccines for Zika and Dengue have high growth potential. Markets for vaccines for conditions such as viral hemorrhagic fevers depend on the severity and occurrence of the next outbreak and the decision of health authorities to incorporate immunization against the disease in its national programs. The vaccine market for respiratory syncytial virus is also expected to grow at high CAGR because of the expected launch of Nirsevimab by AstraZeneca/Sanofi in 2023.
For diagnostics, HIV/AIDS, tuberculosis, malaria and hepatitis C are some of the high-value markets, due to high disease burden as well as the need for clinically confirmed diagnosis. Detection kits for RSV, herpes and influenza are under-utilized in developing economies as the clinician can diagnose these, based on clinical findings, to a certain accuracy. Thus, unless the cost of diagnostic kits is lowered, diagnosis of disease will be a combination of a clinician’s observation of the symptoms and recommendation of a diagnostic test. Resistance to current standards of therapy is a major issue and newer detection kits also feature assays to identify that.
Companies Mentioned
- Alere (Now Abbott)
- Diasorin Spa
- Gilead Sciences
- Glaxosmithkline
- Janssen, Pharmaceutical Company of Johnson & Johnson
- Medicines For Malaria Venture (Mmv)
- Merck
- Novartis
- Orasure Technologies Inc.
- Roche Diagnostics
- Sanofi, Sanofi Pasteur
- Seqirus, a Csl Company
- Siemens Healthineers
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 245 |
| Published | December 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 72.4 Billion |
| Forecasted Market Value ( USD | $ 106.3 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
